These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 1320729)

  • 1. The cost of treating small cell lung cancer.
    Rosenthal MA; Webster PJ; Gebski VJ; Stuart-Harris RC; Langlands AO; Boyages J
    Med J Aust; 1992 May; 156(9):605-10. PubMed ID: 1320729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic and therapeutic approaches to lung cancer in Canada and their costs.
    Evans WK; Will BP; Berthelot JM; Wolfson MC
    Br J Cancer; 1995 Nov; 72(5):1270-7. PubMed ID: 7577481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment pathways, resource use and costs in the management of small cell lung cancer.
    Oliver E; Killen J; Kiebert G; Hutton J; Hall R; Higgins B; Bourke S; Paschen B
    Thorax; 2001 Oct; 56(10):785-90. PubMed ID: 11562518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of increasing the dose intensity of chemotherapy with granulocyte colony-stimulating factor in small-cell lung cancer: based on data from the Medical Research Council LU19 trial.
    Bojke L; Sculpher M; Stephens R; Qian W; Thatcher N; Girling D
    Pharmacoeconomics; 2006; 24(5):443-52. PubMed ID: 16706570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating the cost of lung cancer diagnosis and treatment in Canada: the POHEM model.
    Evans WK; Will BP; Berthelot JM; Wolfson MC
    Can J Oncol; 1995 Dec; 5(4):408-19. PubMed ID: 8770457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-intensive therapy for extensive-stage small cell lung cancer and extrapulmonary small cell carcinoma: long-term outcome.
    Elias AD; Skarin AT; Richardson P; Ibrahim J; McCauley M; Frei E
    Biol Blood Marrow Transplant; 2002; 8(6):326-33. PubMed ID: 12108918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
    Han JY; Cho KH; Lee DH; Kim HY; Kim EA; Lee SY; Lee JS
    J Clin Oncol; 2005 May; 23(15):3488-94. PubMed ID: 15908658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost analysis of lung cancer management in South Western Sydney.
    Kang S; Koh ES; Vinod SK; Jalaludin B
    J Med Imaging Radiat Oncol; 2012 Apr; 56(2):235-41. PubMed ID: 22498199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of cancer chemotherapy: an economic evaluation of a randomized trial in small-cell lung cancer.
    Goodwin PJ; Feld R; Evans WK; Pater J
    J Clin Oncol; 1988 Oct; 6(10):1537-47. PubMed ID: 2845011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economics of the clinical management of lung cancer in France: an analysis using a Markov model.
    Chouaïd C; Molinier L; Combescure C; Daurès JP; Housset B; Vergnenègre A
    Br J Cancer; 2004 Jan; 90(2):397-402. PubMed ID: 14735183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management and costs of treating lung cancer patients in a university hospital.
    Dedes KJ; Szucs TD; Bodis S; Joerger M; Lowy A; Russi EW; Steinert HC; Weder W; Stahel RA
    Pharmacoeconomics; 2004; 22(7):435-44. PubMed ID: 15137882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic and quality-of-life aspects of treating small cell lung cancer.
    Graham P; Boyages J
    Pharmacoeconomics; 1993 Jun; 3(6):446-53. PubMed ID: 10146879
    [No Abstract]   [Full Text] [Related]  

  • 13. [Current perspectives in the management of small cell lung cancer].
    Fujita J; Saijo N
    Gan No Rinsho; 1985 Jan; 31(1):1-19. PubMed ID: 2984443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pharmacoeconomic evaluation of cisplatin in combination with either etoposide or etoposide phosphate in small cell lung cancer.
    Doyle JJ; Dezii CM; Sadana A
    Semin Oncol; 1996 Dec; 23(6 Suppl 13):51-60. PubMed ID: 8996576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost of combined modality interventions for stage III non-small-cell lung cancer.
    Evans WK; Will BP; Berthelot JM; Earle CC
    J Clin Oncol; 1997 Sep; 15(9):3038-48. PubMed ID: 9294466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost of lung cancer in Turkey.
    Cakir Edis E; Karlikaya C
    Tuberk Toraks; 2007; 55(1):51-8. PubMed ID: 17401794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: a mature follow-up report.
    Fetscher S; Brugger W; Engelhardt R; Kanz L; Hasse J; Frommhold H; Lange W; Mertelsmann R
    Ann Oncol; 1999 May; 10(5):561-7. PubMed ID: 10416006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An estimate of the cost of conducting phase II trials in lung cancer.
    Evans WK; Dahrouge S; Stapleton J; Quinn C; Pollock D; Waterfield B; Lister D; Hansel F; Smith A
    Lung Cancer; 2000 May; 28(2):85-95. PubMed ID: 10717326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Costs associated with intravenous chemotherapy administration in patients with small cell lung cancer: a retrospective claims database analysis.
    Duh MS; Reynolds Weiner J; Lefebvre P; Neary M; Skarin AT
    Curr Med Res Opin; 2008 Apr; 24(4):967-74. PubMed ID: 18282373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment and prognosis of 77 cases of small cell lung cancer].
    Shao YJ; Wang YY; Meng CT; Wang YZ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Aug; 32(4):394-7. PubMed ID: 20868596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.